Richard Huhn

Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

Biothera, Inc. develops natural gluco polysaccharide that engages and directs natural innate immune systems. The company was founded by Daniel Conners in 1997 and is headquartered in Eagan, MN.

Cocoon Biotech, Inc. develops and manufactures medicines for osteoarthritis patients. The company was founded by Ailis Tweed-Kent in 2013 and is headquartered in Cambridge, MA.

SRI International provides contract research and development services. It is an independent, nonprofit research institute conducting client-sponsored research and development for government agencies, commercial businesses, foundations, and other organizations. The company was founded in 1946 and is headquartered in Menlo Park, CA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Tunnell Consulting, Inc. provides technical, organizational and operational consulting services. It provides life sciences technical services, process and organizational excellence services, strategy and supply chain management services. The firm serves in the area of pharmaceutical, government and biotechnology departments. The company was founded in 1962 and is headquartered in King of Prussia, PA.

CellMedical SA operates medical diagnostic laboratories. The company is headquartered in Thessaloniki, Greece.

Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom.

Acetylon Pharmaceuticals, Inc. develops pharmaceutical technology. It develops novel small molecule drugs which targets epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The company was founded by Ralph Mazitschek, Kenneth C. Anderson, Marc A. Cohen, James E. Bradner, and Walter C. Ogier in October 2008 and is headquartered in Boston, MA.

The King's Fund organizes healthcare conferences and other events. The company was founded in 1897 and is headquartered in London, the United Kingdom.

Oncimmune Ltd. provides clinical testing services for cancer detection. The firm develops early cancer detection tests for lung, breast, colorectal, prostate, stomach, pancreatic and ovarian cancers. The company was founded by John F. R. Robertson in 2003 and is headquartered in Nottingham, the United Kingdom.

Thetis Pharmaceuticals LLC is a biopharmaceutical company. It improves the lives of patients suffering from gastrointestinal diseases. The company’s proprietary HEALER™ technology platform enables the pharmaceutical development of bioactive lipids, including resolving and other fatty acids, that actively regulate inflammation resolution and tissue repair. Its technologies are pro-resolving lipids and intellectual property. The company was founded by Frank C. Sciavolino, Banavara L. Mylari and Gary Mathias in 2011 and is headquartered in Southport, CT.

Perspectum Ltd. provides technology solutions for diagnosing and staging liver disease. The company was founded by Rajarshi Banerjee, Stefan Karl Neubauer, Matthew David Robson, Alastair Cavanagh, James Hugh Charteris Mallinson and John Michael Brady on September 18, 2012 and is headquartered in Oxford, the United Kindgom.

Genomics England Ltd. runs and delivers 100,000 genomes project. Its flagship project sequences 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. The company was founded by Jeremy Hunt on July 5, 2013 and is headquartered in London, the United Kingdom.

PlaqueTec Ltd. develops a liquid biopsy system platform technology that provides unparalleled resolution of the biological processes that cause coronary artery disease. The firm’s Liquid Biopsy System addresses the underlying biomarker collection problems preventing advances in CAD research. The company was founded by Stephen Blatcher in 2000 and is headquartered in Cambridge, the United Kingdom.

Thrombolytic Science International LLC operates as a vascular medicine and biotech company. The company was founded by Alexis Wallace and Victor Gurewich and is headquartered in Cambridge, MA.

PhESi LLC provides drug and clinical development services for life sciences companies. The private company is based in East Lyme.

AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA.

Hibercell, Inc. specializes on tumor dormancy detection and therapeutics. It provides treatment for primary tumors, metastatic cancer. The company was founded by Alan Rigby, Julio Aguirre-Ghiso, and Ari Nowacek and is headquartered in New York, NY.

Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010.

Part of Compass Pathways Plc, COMPASS Pathfinder Holdings Ltd. is an investment holding British company. The company is based in London, UK and was founded in 2017.

Noxsudor Therapeutics Ltd. manufactures capsules that control sweating.

RYSE Asset Management LLP (RYSE) is a venture capital firm founded in 2010 by Atique Mirza. The firm is headquartered in London, the United Kingdom.

The Conduit Connect Ltd. is a private membership platform for high net worth, sophisticated, and professional impact investors. The company is based in London, UK. The British company connects founders who are building scalable, for-profit, impact-driven businesses to capital and expert resources. The company source and connects the most promising high growth impact investing opportunities to mission-aligned investors. The company was founded in 2018, and the CEO is Eva-Maria Dimitriadis.

Perspectum Group Plc engages in the sale of diagnostic products via a software-as-a-medical device platform. Its products combine expertise in image formation, magnetic resonance image analysis and artificial intelligence to support healthcare provider diagnosis, treatment decision-making, and monitoring of the progression of chronic metabolic diseases, multi-organ pathologies and cancer, and determine whether the patient is responding to therapy. Its products include Liver MultiScan, MRCP+, Hepatica, and CoverScan MD. The company was founded by Matthew Robson on June 10, 2021 and is headquartered in Oxford, the United Kingdom.

Valeas Capital Partners Management LP (Valeas Capital Partners) is a private equity firm founded in 2021 by Rob O'Connor Little and Edward A. Woiteshek. The firm headquartered in San Francisco, California.